Back to Search Start Over

Rare perianal extramammary Paget disease successfully treated using topical Imiquimod therapy.

Authors :
Dos Santos JS
Bonafé GA
Pereira JA
Kanno DT
Martinez CAR
Ortega MM
Source :
BMC cancer [BMC Cancer] 2018 Sep 25; Vol. 18 (1), pp. 921. Date of Electronic Publication: 2018 Sep 25.
Publication Year :
2018

Abstract

Background: Perianal Paget's disease (PPD) is a rare intraepithelial adenocarcinoma of the anal margin. Primary PPD likely represents intra-epithelial neoplasm from an apocrine source, whereas secondary disease may represent "pagetoid" spread from an anorectal malignancy.<br />Case Presentation: Histologic CDX-2 and CK20 are hallmark markers for colorectal-derived Paget's cells. Interestingly, our primary PPD patient presented both positive and no internal malignancy was identified. In addition, a negative CK7 marker was observed in our case in contrast with previously reported. Surgical excision is the standard treatment; however, previous studies have demonstrated good response with Imiquimod 5% cream in patients with vulval extramammary Paget disease (EMPD). The efficiency of Imiquimod treatment for PPD has not been well described. Our PPD patient was successfully treated using Imiquimod 5% cream.<br />Conclusions: This study describes a primary cutaneous PPD patient CDX-2+/CK20+/CK7- without invasion of the dermis and no associated colorectal carcinoma effectively treated using topical Imiquimod therapy, suggesting that Imiquimod might potentially be considered as a first-line treatment for PPD.

Details

Language :
English
ISSN :
1471-2407
Volume :
18
Issue :
1
Database :
MEDLINE
Journal :
BMC cancer
Publication Type :
Academic Journal
Accession number :
30253739
Full Text :
https://doi.org/10.1186/s12885-018-4815-6